Anixa Biosciences (ANIX) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $84.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | RTSN |
|---|---|---|
| Share price | $2.44 | $10.51 |
| Market cap | $84.82M | $87.57M |
| 1-day change | -6.15% | -19.22% |
| YTD return | -21.79% | — |
| 1-year return | -43.78% | — |
| 5-year return | -38.69% | — |
| EPS (TTM) | $-0.32 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-10.93M | — |
| 52-week high | $5.46 | $18.64 |
| 52-week low | $2.32 | $9.23 |
| Distance from 52-week high | -55.31% | -43.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +296.31% | +391.63% |
| Average volume | 282.29K | 144.93K |
| Shares outstanding | 34.76M | 8.33M |
| Employees | 4 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ANIX vs RTSN FAQ
Which is bigger, Anixa Biosciences or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $84.82M for Anixa Biosciences (ANIX).
Are Anixa Biosciences and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.